Trial Profile
Phase I Clinical trial of personalized peptide vaccine in combination with humanized anti-IL6 receptor monoclonal antibody for refractory colorectal cancer patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Sep 2020
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Colorectal cancer vaccine; Montanide ISA-51
- Indications Colorectal cancer
- Focus Adverse reactions
- 23 Sep 2020 Status changed from suspended to discontinued.
- 06 Apr 2017 Status changed from recruiting to suspended.
- 14 Mar 2012 New trial record